Brief: Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
11/12/2023 13:24
Dec 11 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM ANNOUNCES IOMAB-B PRODUCES HIGH RESPONSE RATES
AND
SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN RELAPSED
REFRACTORY AML PATIENTS WITH ACTIVE DISEASE OVERCOMING TP53
MUTATION
* ACTINIUM PHARMACEUTICALS INC - OVERALL, TWENTY-FOUR
PERCENT
(37/153) OF PATIENTS ENROLLED ON SIERRA HAD A TP53 MUTATION
Source text for Eikon: ID:nPn6gyQ42a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities